IDO1 and neoplasm: Inhibition of relevant immunosuppressive pathways identified in the tumor microenvironment (e.g., PD-1, indoleamine-2,3-dioxygenase 1 (IDO1)) can be an effective strategy to strengthen antitumor immunity and stop tumor growth [40,41].